Shire PLC: Vyvanse programme cancelled in NSS and delayed in MDD

BUY, Fair Value 2160p vs. 2250p (+7%)

News published on May Friday 3, 2013
Share on

Yesterday, Shire presented its Q1 earnings driven by sales significantly lower than the expected (mainly due to an orphan disease franchise suffering from competition by Sanofi and Dermagraft sales still under pressure) and SG&A costs very well contained. Thus even if Shire decreases its top line guidance, the company can maintain its full year bottom line guidance, i.e. an EPS at around USD6.72. However according to us the main disappointment concerns the prioritisation on R&D projects leading to the cancellation of the Vyvanse programme in Schizophrenia. Also the two main catalysts for the stock expected for the second half of this year are delayed to the first part of 2014. All in all, we adjust our FV to 2,160p.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities